-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：我們將UHS的12個月目標價從243美元下調至200美元，相當於我們2026年每股收益預期的8.7倍，低於同業平均水平，也低於UHS五年曆史平均預期市盈率11.9倍。我們將2026年每股盈餘預期從23.39美元下調至22.95美元，並將2027年預期從25.67美元下調至25.48美元。第一季住院量與上一季持平，受到冬季惡劣天氣和流感/呼吸道疾病流行程度較輕等季節性不利因素的影響。 近期《平價醫療法案》(ACA)電子支付稅收抵免(EPTC)的到期也帶來了挑戰，UHS預計，與2025年第一季相比，ACA調整後的入院人數將下降近5%。 UHS維持了先前的預測，即全年ACA交易所的交易量將下降25%-30%，這約佔2025年急性護理業務調整後入院人數的6%，以及急性護理業務收入的不到5%。 UHS預計，這些因素將導致其2026年稅前利潤減少7,500萬美元，與先前的預期一致。
Related Articles
Asia
Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%
Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.
$ASX:TLX
Asia
Zozo's Profit Climbs 6% in Fiscal Year 2025
Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.
$TYO:3092
Asia
EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure
EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.
$ASX:EML